NCT04256707Phase 1, phase 2Completed

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Study sponsor: Karyopharm Therapeutics Inc · KPTI

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-07-31Actual
Enrollment · participants80Actual
Source updated2026-10-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.